Condition: Skin Diseases · Sponsor: BeOne Medicines
This is the first-in-human study of BG-A3004. The study will evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of BG-A3004 after single and multiple doses administered in different dose levels in healthy participants (Part A) and patients with immune-mediated skin diseases (Part B), respectively. Study details include: * The study duration will be approximately 3 years. * The treatment duration will be 1 dose for Part A and 4 doses for Part B. * Safety follow-up period is 168 days after the last dose
This description comes directly from the study's public registry record.
Study Director · +1-877-828-5568 · clinicaltrials@beonemed.com
Always discuss trial participation with your own doctor first.
| Beijing Tongren Hospital, Cmu | Beijing, Beijing Municipality, China | Recruiting |
| Peking University First Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The Second Hospital of Hebei Medical University | Shijiazhuang, Hebei, China | Recruiting |
| Suzhou Municipal Hospital | Suzhou, Jiangsu, China | Recruiting |
| Hangzhou First Peoples Hospital | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07412691